From risk marker to treatment trigger: biomarker-guided decision-making in acute heart failure
This narrative review argues that acute heart failure biomarker research must shift from validating prognostic risk to establishing clinically actionable treatment triggers, highlighting congestion biomarkers like CA-125 and the STRONG-HF trial's embedded decision-making framework as the most promising pathways for future guideline-impacting studies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a person's heart struggles to pump blood effectively, fluid can begin to back up, filling the lungs and swelling the legs. This condition, known as acute heart failure, is a medical emergency that sends millions of people to hospitals every year. For decades, doctors have relied on a specific type of chemical signal found in the blood to diagnose this problem. These signals, produced by the heart when it is under stress, act like a smoke alarm, telling physicians that something is wrong. However, a critical question has remained unanswered for a long time: does checking the level of this smoke alarm after the initial diagnosis actually help doctors decide what to do next? In other words, can a blood test result tell a doctor exactly how much medication to give, when to send a patient home, or whether to change a treatment plan to save a life?
A new review of medical research, published by scientists from Bogomolets National Medical University, tackles this exact question. The authors examined decades of studies to see if blood markers are truly useful as tools for making treatment decisions, or if they are merely labels that tell us how sick a patient is. They found that while many blood tests are excellent at predicting who might get sicker or die, very few have been proven to change the outcome when used to guide specific medical actions. The review argues that the medical community has spent too much time proving that these markers predict risk, and not enough time proving that acting on them improves health.
The story begins with the most famous of these markers, known as natriuretic peptides. These are the standard tools doctors use to confirm a diagnosis of heart failure. If the levels are high, the diagnosis is likely correct. For years, researchers hoped that by measuring these levels repeatedly in patients who had been sent home from the hospital, doctors could adjust medication doses to keep the levels low and prevent the patient from returning. The review looked at the evidence for this strategy and found it to be mixed. While the levels do go down when a patient gets better, simply trying to hit a specific number with medication has not consistently prevented hospital readmissions or death in large studies. The markers work well as a diagnostic tool, but they have not yet proven to be a reliable trigger for changing outpatient therapy.
The search for a better guide led researchers to look at markers that measure congestion directly. Congestion is the actual buildup of fluid in the body, which causes the symptoms of heart failure. One such marker, called CA-125, is released by the lining of the body's internal cavities when they are stretched by fluid. Unlike the standard heart markers, which can be influenced by obesity or kidney issues, CA-125 seems to track the fluid itself. In a few specific studies, doctors used rising or falling levels of CA-125 to decide how much diuretic medication to give a patient. These trials showed a promising result: patients whose treatment was guided by this marker had fewer deaths and fewer returns to the hospital. However, the review notes a significant caveat. These positive results came from a single group of researchers in one location. Until independent teams in different hospitals repeat these findings, the medical community cannot be certain that this approach works everywhere.
Another area where blood markers are used to guide treatment involves iron. Iron deficiency is common in heart failure patients and is linked to worse symptoms. Current medical guidelines recommend giving intravenous iron to patients whose blood tests show low levels of a specific protein called ferritin or low saturation of transferrin. This is a clear example of a blood test acting as a trigger for a specific treatment. Yet, the review highlights that the evidence supporting this rule is more complicated than it appears. Over the last sixteen years, seven major trials have tested this approach. While some showed benefits, others did not reach statistical significance, and the results have been inconsistent. Furthermore, most of these trials were funded by the companies that make the iron treatments, raising questions about whether the definition of "low iron" is perfect for everyone. A recent large study even suggested that the treatment might help men more than women, indicating that a single blood test threshold might not apply equally to all patients.
The review also looked at newer, more complex panels of markers that measure inflammation and other body processes. These markers are excellent at predicting who is at high risk, but they currently offer no clear path for action. Knowing a patient is at high risk does not tell a doctor which specific drug to change or when to stop treatment. The authors point out that the field is stuck in a cycle of proving risk without proving that acting on that risk helps.
The most successful example of a blood marker guiding a decision comes from a trial called STRONG-HF. In this study, doctors did not just measure a marker to see if a patient was sick; they built the treatment plan around the marker's changes. Patients were given a rapid schedule of medication increases, but this schedule was strictly controlled by safety rules. If a patient's blood marker for heart stress rose by a certain amount, the doctors were required to pause the medication increase. This approach, which used the marker as a safety brake and a guide for speed, significantly reduced the number of deaths and hospital readmissions. This trial stands out because the marker was not just a label; it was an active part of the decision-making process.
Despite this success, the review concludes that the path forward is not simple. The biggest hurdle is that proving a marker can guide treatment requires a different kind of study than simply observing patients. It requires a trial where the marker itself dictates the treatment, and where that strategy is compared against standard care. Currently, most research stops at the observation stage. The authors argue that the most promising next step is to take the idea of using congestion markers like CA-125 and test them in large, independent, multi-center trials similar to the STRONG-HF design. Until such trials are completed and confirmed by independent groups, the idea that these blood tests are ready to fully guide therapy remains an aspiration rather than a proven fact. The goal is to move from knowing who is at risk to knowing exactly what to do about it.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.